Clinical Trial Update: Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Vudalimab (XmAb20717) in combination with standard of care for metastatic castration-sensitive prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Vudalimab (XmAb20717)

Snippet

Sponsor: Emory University | Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 | Status: TERMINATED